池 苇1，孙玥妍2，毛旭喆1，宫弋婷1，张哲博1，于瀚普1，裴宝鑫1，李 杰1*
（1.佳木斯大学公共卫生学院，黑龙江省痛风研究重点实验室，佳木斯 154000；
2.佳木斯大学临床医学院，佳木斯 154000）
摘 要：益生菌应用于人群疾病治疗和预防过程中首先要保证其安全性，该研究通过体外和小鼠实验，对前期所筛选得到的一株具有潜在降尿酸功效的短乳杆菌SLlac-19开展了系统的安全性评价。结果表明：短乳杆菌SLlac-19在胃液处理3h后存活率达95.26%，肠液处理4h后存活率进一步提升至98.84%，表明菌株具有一定的胃肠道耐受能力；此外，抗生素敏感性实验和溶血实验结果发现，该菌株对多种抗生素均有敏感反应且不具有溶血作用。口服毒性实验结果发现，小鼠连续服用短乳杆菌SLlac-19 7d后，其体重、生理状态、脏器指数、血常规参数以及肝肾功能指标（谷丙转氨酶、谷草转氨酶、肌酐和尿素氮）相比对照组无显著性差异（P＞0.05）。上述结果表明：短乳杆菌SLlac-19具有良好的安全性，可进一步应用于高尿酸血症的治疗和预防等相关研究。
关键词：益生菌；安全性；短乳杆菌；降尿酸；高尿酸血症
中图分类号：TS201.3 文献标识码：A 文章编号：1674-506X（2026）01-0039-0007
Safety Evaluation Analysis of the Strain of Lactobacillus brevis SLlac-19 with Potential Uric Acid Lowering Effect
CHI Wei1，SUN Yueyan2，MAO Xuzhe1，GONG Yiting1，ZHANG Zhebo1，YU Hanpu1，PEI Baoxin1，LI Jie1*
（1.Heilongjiang Key Laboratory of Gout Research，School of Public Health，Jiamusi University，Jiamusi 154000，China；
2.School of Clinical Medicine，Jiamusi University，Jiamusi 154000，China）
Abstract：When applying probiotics to the treatment and prevention of human diseases，its safety must be ensured first. In this study，in vitro and mice experiments were used to systematically evaluate the safety of the strain of Lactobacillus brevis SLlac-19 with potential uric acid lowering effect screened in the earlier stage. The results showed that the survival rate of SLlac-19 was 95.26% after 3 h of gastric fluid treatment，and the survival rate was further increased to 98.84% after 4h of intestinal fluid treatment，indicating that the strain had a certain gastrointestinal tolerance；in addition，the results of antibiotic susceptibility test and hemolysis test showed that the strain was sensitive to a variety of antibiotics and did not have hemolytic effect. The results of oral toxicity test showed that there was no statistically significant difference in body weight，physiological state，organ indicators，blood routine indicators，liver and kidney functional indicators （alanine aminotransferase，aspartate aminotransferase，creatinine and urea nitrogen） of mice compared with the control group after 7 d of continuous administration of Lactobacillus brevis SLlac- 19 （P＞0.05）. The above results showed that Lactobacillus brevis SLlac-19 had a good safety and could be used in the research and treatment and prevention of hyperuricemia.
Keywords：probiotics；safety；Lactobacillus brevis；uric acid lowering；hyperuricemia
doi：10.3969/j.issn.1674-506X.2026.01-005
